腹腔热灌注化疗与间歇性肿瘤细胞减灭术联合择期剖宫产
一例40岁妊娠27周确诊III期上皮性卵巢癌患者,接受新辅助化疗后于足月行剖宫产同时行间歇性肿瘤细胞减灭术和腹腔热灌注化疗(HIPEC),干预耐受良好,分娩健康新生儿,术后经过平稳,随访22个月无病生存。作者据此展示围产期HIPEC的可行性。
要点
- 妊娠27周确诊III期上皮性卵巢癌,新辅助化疗后足月剖宫产联合间歇性肿瘤细胞减灭术和HIPEC。
- 干预耐受良好,分娩健康新生儿,术后经过平稳,随访22个月无病生存。
- 作者认为围产期HIPEC可行,不应因围产期状态而危及最佳肿瘤治疗。
核心结论
- 作者展示围产期HIPEC的可行性,认为对于其他方面健康的患者,不应因围产期状态而危及最佳肿瘤治疗。
研究设计与样本
- 个案报告:一例40岁妊娠27周确诊III期上皮性卵巢癌患者,接受新辅助化疗后于足月行剖宫产联合间歇性肿瘤细胞减灭术和HIPEC。
主要发现
- 干预耐受良好,分娩健康新生儿,术后经过平稳,随访22个月无病生存。
临床怎么用
- 作者认为围产期HIPEC可行,不应因围产期状态而危及最佳肿瘤治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ovarian cancer is rare during pregnancy. For patients beyond 20 weeks of gestation who choose to continue the pregnancy, neoadjuvant chemotherapy may be initiated, followed by interval debulking surgery. Hyperthermic intraperitoneal chemotherapy (HIPEC) may be used with interval debulking surgery for stage III epithelial ovarian cancer, but data are lacking on its administration in the peripartum period. CASE: We illustrate the case of a 40-year-old patient diagnosed with stage III epithelial ovarian cancer at 27 weeks of gestation who underwent neoadjuvant chemotherapy followed by cesarean delivery at term along with interval debulking surgery and HIPEC. The intervention was well tolerated and resulted in the birth of a healthy neonate. The postoperative period was unremarkable, and the patient is disease-free after 22-months of follow-up. CONCLUSION: We demonstrate the feasibility of peripartum HIPEC. Optimal oncologic care should not be jeopardized by the peripartum state of an otherwise healthy patient.
引用
- Tremblay E, Pina A, Avon-Després C, et al. Hyperthermic Intraperitoneal Chemotherapy and Interval Debulking Surgery in Conjunction With Elective Cesarean Delivery. Obstet Gynecol. 2023. PMID: 37023444. doi:10.1097/AOG.0000000000005146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。